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Abstract
Introduction
Delayed graft function is a prevalent clinical problem in renal transplantation for which there
is no objective system to predict occurrence in advance. It can result in a significant
increase in the necessity for hospitalisation post-transplant and is a significant risk factor for
other post-transplant complications.
Methodology
The importance of microRNAs (miRNAs), a specific subclass of small RNA, have been
clearly demonstrated to influence many pathways in health and disease. To investigate the
influence of miRNAs on renal allograft performance post-transplant, the expression of a
panel of miRNAs in pre-transplant renal biopsies was measured using qPCR. Expression
was then related to clinical parameters and outcomes in two independent renal transplant
cohorts.
Results
Here we demonstrate, in two independent cohorts of pre-implantation human renal allograft
biopsies, that a novel pre-transplant renal performance scoring system (GRPSS), can
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determine the occurrence of DGF with a high sensitivity (>90%) and specificity (>60%) for
donor allografts pre-transplant, using just three senescence associated microRNAs com-
bined with donor age and type of organ donation.
Conclusion
These results demonstrate a relationship between pre-transplant microRNA expression lev-
els, cellular biological ageing pathways and clinical outcomes for renal transplantation.
They provide for a simple, rapid quantitative molecular pre-transplant assay to determine
post-transplant allograft function and scope for future intervention. Furthermore, these
results demonstrate the involvement of senescence pathways in ischaemic injury during the
organ transplantation process and an indication of accelerated bio-ageing as a conse-
quence of both warm and cold ischaemia.
Introduction
Increasing demand for renal transplantation has resulted in the use of kidneys which previ-
ously would have been considered marginal and this combined with an increase in Donation
after Circulatory death (DCD) has increased the prevalence of renal allografts at risk of Delayed
graft function (DGF). DGF is most commonly defined as the need for dialysis within one week
post-transplant [1,2]. DGF is a consequence of Acute Kidney Injury (AKI) related to peri-
transplant processes and results in prolonged post-operative hospitalisation. Although previ-
ous work has reported no deleterious impact of DGF on long term survival, it remains to be
seen if this is maintained in the context of a changing donor population. Consequently, this
important prognostic factor for allograft outcome is likely to remain a significant clinical chal-
lenge for the foreseeable future, as the use of Extended Criteria Donors (ECD) and DCD kid-
neys to meet the shortfall in available kidneys on a growing transplant waiting list, is associated
with an increased incidence of DGF [3,4]. Furthermore, although our understanding of the
clinical risk factors has improved this has not translated into the development of therapies to
attenuate or treat DGF.
Until recently, donor chronological age has been the most widely accepted and utilised crite-
rion in assessment of an organ for transplantation. We, and others, have demonstrated that
allograft biological age, determined by the expression level of CDKN2A pre-transplant, is a
superior prognostic and predictive marker to donor age in this context [5,6,7]. Notably, how-
ever, expression of this marker, has already shown an association with DGF in one study [5],
opening an avenue to an improved molecular characterisation for this problem and thus better
risk benefit analysis and better informed patient management.
The CDKN2 locus is complex and subject to a range of spatio-temporal and developmental
epigenetic regulation, which integrates expression of its gene products to a range of stress and
damage related biochemical pathways (e.g. mTOR, P13K, TGF-β). Recent studies have impli-
cated epigenetic regulation by microRNAs as critical regulators of the CDKN2 locus, renal
development as well as physiological processes [8,9]. Indeed, they have been used to provide a
valuable post-transplant signature of renal function and allograft rejection.
MicroRNAs are small (18–25 nucleotides), non-coding, single-stranded RNAmolecules
that are involved in the regulation of a variety of biological processes, including embryogenesis,
differentiation, and senescence [10,11,12]. MicroRNAs are also critical for mRNA stability and
microRNA and DGF
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are involved in the regulation of gene silencing [13]. This has led us to hypothesis that miRNAs
associated with such pathways may be potential biomarkers for DGF. Two miRNAs, hsa-mir-
217 and hsa-mir-125b, involved in cellular stress and damages responses are of particular inter-
est in this context, as they help regulate biological ageing processes common across taxa and as
mediators of CDKN2 loci transcript expression.
In this study, we have sought to determine in a retrospective analysis of pre-transplant allo-
graft biopsies, if these miRNAs associate with DGF, or where interrelated with pre-transplant
parameters that might influence outcome, or post-transplant performance (e.g. cold ischaemia
time, type of organ donation, ECD) that might impact upon DGF.
We have hypothesised that such a signature may identify molecular characteristics that
offer insight into the clinical phenotype of delayed graft function and potential novel therapeu-
tic targets.
Materials and Methods
Renal allograft recipients and Biopsy specimens
Cortical needle biopsies of renal allografts were obtained pre-transplant (N = 94, placed in
RNA1later(Ambion, USA) and stored at -80°C for further analysis. Donor and recipient char-
acteristics are shown in Table 1. This study as well as consent procedure was approved by the
Regional Ethics Committee of North Glasgow NHS Trust (GN10SU334, 10/S0704/42). Donors
from the national pool donated their organs for transplantation. The recipient of the organ
provided pre-operative written informed consent and records are stored at South Glasgow Uni-
versity Hospital.
Samples were anonymised and subsequently analysed. The validation cohort had a separate
ethical approval granted (Innsbruck Medical University and Universitätsklinikum Tübingen)
and full written consent was collected for each subject (Table A in S1 Data.). None of the trans-
plant donors were from a vulnerable population and all donors or next of kin provided written
informed consent that was freely given.
Total RNA from kidney biopsies was extracted using TRI1 Reagent according to the manu-
facturer’s instructions (Invitrogen, UK) and stored at -80°C for further analysis. Quantitative
and qualitative analysis of isolated RNA was performed for each sample; this included spectral
analysis (A260/280 nm), non-denaturing agarose electrophoresis and expression profile of 18S
rRNA. RNA extraction for validation cohort can be found in S1 Data.
MicroRNA expression and data analysis
MicroRNA profiles were determined in pre-transplant renal biopsies using micro-fluidic cards
comprising of 754 independent microRNAs (TaqMan1 Array Human MicroRNA A+B Cards
Set v3.0, Applied Biosystems). 10 renal biopsies were used for profiling studies (5 good per-
forming allografts and 5 poor performing allografts).
1 μg of total RNA for each card in the set was reverse transcribed using Megaplex™ Primer
Pools, Human Pools Set v3.0 and TaqMan1MicroRNA Reverse Transcription Kit according
to the manufacturer’s instructions (Applied Biosystems). QPCR was carried out on 7900HT
Real-Time PCR system (Applied Biosystems) using thermal profiles recommended by the
manufacturer. Amplification profiles for each sample and target were analysed individually
and profiles with Ct above 35, bad passive reference signal, noise spike and high noise were
removed from further analyses. Data analysis was performed using RQManager 1.2 and Real-
Time1StatMiner (Integromics). Data were normalised against the following endogenous con-
trols: RNU44, RNU48 and MammU6 or U6snoRNA depending on the card used. The
comparative threshold cycle method (ΔΔCT) was used to quantify relative gene expression,
microRNA and DGF
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Table 1. Patient clinical and experimental characteristic. Continuous variables are expressed as mean with standard deviation, whereas categorical var-
iables are expressed as proportions.
Variable Mean (Min-Max)/ Proportion Standard deviation (if applicable)
DONOR
Donor gender (males/females) 52/42
Donor age (years) 46.6 (11–78) 17.8
Donor serum creatinine at retrieval (μmol/L) 92.2 (23–786) 84.4
Ethnicity (Caucasian: Asian) 93:1
Donor type
DBD/DCD 67/27
ECD 32
DBD-ECD 24
DCD-ECD 8
Cause of Death
Intracranial Haemorrhage 43
Hypoxic Brain Injury 26
Trauma 9
Tumour 5
Meningitis 4
Intracranial Thrombus 6
Respiratory Failure 1
Donor hypotension (N) 62
Donor hypertension (N) 54
RECIPIENT
Recipient gender (males/females) 59/35
Recipient age (years) 50.7 (20–75) 12.5
Aetiology of Renal Failure
IgA Nephropathy 14
Glomerulonephritis 14
APKD 19
Reﬂux /Obstructive Uropathy 9
Hypertension 4
Diabetes Mellitus 6
Unknown 12
Chronic pyelonephritis 4
HSP 1
Alport’s Syndrome 1
Reno-vascular 2
Drug related 2
Stone disease 2
SLE 2
HUS 1
FSGS 1
Previous Transplant
0 77
1 15
2 2
HLA Mismatch
HLA- A (0/1/2) 29/38/27
(Continued)
microRNA and DGF
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and the obtained quantification was transformed to exponential value 2-ΔΔCT [14]. MicroRNA
expression profile generation for validation cohort is described in S1 Data.
QPCR
For each individual RT reaction 10 ng of total RNA from each sample was used and reverse
transcription was performed using TaqMan1MicroRNA Reverse Transcription Kit (Life Tech-
nologies Inc., UK). RT product was further amplified using individual microRNA1Taqman
assays. hsa-miR-217 (002337) and hsa-miR-125b (000449) expression was normalised against
the following endogenous controls: RNU44 (001094), RNU48 (001006) and U6snoRNA
(001973) for each sample.
For gene expression analysis, 1 μg of total RNA was reverse transcribed using SuperScrip-
t1II Reverse Transcriptase (Life Technologies Inc., UK) and then qPCR was performed. The
gene expression was analysed using TaqMan1gene expression assays for CDKN2A
(Hs00923894_m1), ANRIL (Hs04406279) and normalised against HPRT1 (Hs02800695_m1).
The comparative threshold cycle method (ΔΔ CT) was used to quantify relative gene expres-
sion, and the obtained quantification was transformed to exponential value 2- ΔΔ CT [14]. RNA
extracted from the kidney of a 41 year old healthy donor was used as a calibrator for all
experiments.
Statistics
Statistical analysis of microRNA expression was performed using the SPSS statistical package
(v17). Spearman correlations and appropriate parametric or non-parametric tests were used to
compare variables.
Logistic regression analyses were performed to demonstrate any association between differ-
ential microRNA expression in relation to DGF as well as biochemical and clinical parameters.
This was accomplished using a backward stepwise approach, where all variables were added to
the model, and removed based on significance of input to the model. p<0.05 was considered
significant.
Table 1. (Continued)
Variable Mean (Min-Max)/ Proportion Standard deviation (if applicable)
HLA- B (0/1/2) 33/50/11
HLA- DR (0/1/2) 67/24/3
Cold ischaemic time (hours) 13.7 (6–23) 3.9
Immunosuppression
Induction: Basiliximab/ Campath /ATG 80/7/5
Maintenance: Tacrolimus /Sirol/Cyc 92/1/1
Prednisolone 88
Mycophenolatemofetil 87
BPAR 16
DGF 27
Serum creatinine level at 6 months (μmol/L) 125.5 (55–318) 53.2
MDRD4 at 6 months (ml/min/1.73m2) 59.4 (17.6–115.3) 23.1
Serum creatinine level at 1 year (μmol/L) 128.8 (55–377) 57.3
MDRD4 at 12 months (ml/min/1.73m2) 59 (16.2–120) 22.2
doi:10.1371/journal.pone.0146378.t001
microRNA and DGF
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Results
94 pre-perfusion renal biopsies collected upon arrival for transplantation from deceased donors
were included in this study. Patient characteristics are described in Table 1. All kidneys in this
cohort were subsequently transplanted. Mean donor age was 46.6 years and 55% were frommale
donors. 28.7% were donors after circulatory death and 34% of all donors were extended criteria
donors. 4 kidneys had AKI at retrieval with serum Creatinine levels of> 200 μmol/L. However,
none of these kidneys displayed delayed graft function post-transplantation. The overall DGF
rate in this cohort is 28.7%. The mean cold ischaemic time is 13 hours which compares well with
national averages and limits one of the known risk factors for DGF in this cohort.
MicroRNA profiles were determined in pre-transplant biopsies using micro-fluidic cards
comprising 754 independent microRNAs (TaqMan1 Array Human MicroRNA A+B Cards
Set v3.0, Applied Biosystems). For initial profiling, 10 pre-transplant renal allograft biopsies
were used; of these 5 were good performers within 2 years of transplant while the other 5 pre-
sented poor function within the same time frame. Differential expression between good and
poor performers (minimum of two-fold difference) was observed for hsa-miR-505, hsa-miR-
34a, hsa-miR-1275, hsa-miR-125a-5p, hsa-miR-449a, hsa-miR-155, hsa-miR-101#, hsa-miR-
375, hsa-miR-96, hsa-miR-217 and hsa-miR-125b. These microRNAs were further analysed in
the context of other clinical parameters including DGF, serum Creatinine, MRDR4 at 6 and 12
months post-transplant and type of organ donation.
Association analysis
The incidence of DGF was associated with higher donor age (p<0.001), increased CDKN2a/
p16 expression (p = 0.01) and decreased expression of hsa-miR-217 (p<0.0001) and hsa-miR-
125b (p = 0.035) in allografts showing DGF post-transplant compared to these without the
occurrence of DGF (Fig 1). Interestingly, a negative correlation between hsa-miR-217 and
CDKN2A/p16 expression was also noted (cc = -0.392, p = 0.001). Further analysis of the
CDKN2 locus revealed that hsa-miR-217 is positively correlated with ANRIL (CDKN2B-AS1,
cc = 0.289, p = 0.029).
Fig 1. Delayed graft function is related to donor age, CDKN2A/p16 and the expression of hsa-miR-217
and hsa-miR-125b.Gene and MicroRNA expression was assayed using individual TaqMan1assays and
normalised against the following endogenous controls: RNU44, RNU48 and U6snoRNA (for microRNA) and
HPRT1 for CDKN2A. Data presented as mean with 95%CI.
doi:10.1371/journal.pone.0146378.g001
microRNA and DGF
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Lower hsa-miR-125b (p = 0.024) was observed in donors after cardiac death as compared to
donors after brain death, this microRNA was also positively correlated to cold ischaemia time
(cc = 0.227, p = 0.028)
We have also analysed the expression of differentially expressed transcripts and microRNAs
in the context of recovery from transplant related injury measured as the time for serum creati-
nine levels to half (Cr t1/2)[15]. This is defined as the time taken for the serum creatinine level
to drop to half of its peak post-operative value. For immediate functioning grafts this will be
the highest value seen post-transplant. For those with DGF, the peak value is taken as the high-
est creatinine value observed following the last haemodialysis session (Fig 2). Cr t1/2 was sig-
nificantly correlated with the expression of hsa-miR-125b (cc = -0.287, p = 0.006) and allograft
function measured as MDRD4 at 3 months (cc = -0.4010, p<0.0001) and 6 months post-trans-
plant (cc = -0.285, p = 0.006; Table 2). The expression of hsa-miR-217 was positively correlated
with MDRD4 at 12 months (cc = 0.300, p = 0.007; Table 2)
Fig 2. Cr t1/2 calculation and post-transplant organ recovery. A) Cr t1/2 for immediately functioning
grafts, B) Cr t1/2 for DGF requiring haemodialysis.
doi:10.1371/journal.pone.0146378.g002
Table 2. Correlationmatrix of clinical outcome parameters andmiRNA expression.
Spearman's rho Donor age CIT(h) Cr t 1/2 MDRD4_3m MDRD4_6m MDRD4_12m
hsa-miR-125b cc -0.077 0.241* -0.287** 0.168 0.143 0.072
p 0.460 0.020 0.006 0.111 0.180 0.515
hsa-miR-217 cc -0.202 -0.148 -0.157 0.100 0.162 0.300**
p 0.050 0.156 0.138 0.345 0.125 0.007
CDKN2A cc 0.558*** 0.070 0.173 -0.333** -0.327** -0.371**
p 0.0001 0.563 0.160 0.006 0.007 0.003
CIT (h) cc -0.005 1.000 -0.007 0.055 0.025 0.215*
p 0.960 . 0.947 0.605 0.812 0.048
Cr t1/2 cc 0.144 -0.007 1.000 -0.410** -0.285** -0.194
p 0.173 0.947 . 5.88E-05 0.006 0.075
MDRD4_3m cc -0.606*** 0.055 -0.410*** 1.000 0.821*** 0.702***
p 0.0001 0.605 5.88E-05 . 2.20E-23 6.81E-14
MDRD4_6m cc -0.525*** 0.025 -0.285** 0.821*** 1.000 0.762***
p 0.0001 0.812 0.006 2.20E-23 . 2.65E-17
MDRD4_12m cc -0.633*** 0.215* -0.194 0.702*** 0.762*** 1.000
p 0.0001 0.048 0.075 6.81E-14 2.65E-17 .
* p<0.05
** p<0.01 and
***p<0.001.
doi:10.1371/journal.pone.0146378.t002
microRNA and DGF
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Longer term function of renal allograft, measured as MDRD4 at 3, 6 and 12 months,
revealed significant correlations with CDKN2A expression at all-time points (Table 2). When
DGF-related microRNAs were analysed for their correlation with renal allograft function at
post-operative day 3 (POD3), post-operative day 5 (POD5) and post-operative day 7 (POD7),
the expression of hsa-miR-125b was positively correlated with MDRD4 at all time-points while
hsa-miR-217 was associated with renal function on POD5 and POD7 (Table 3).
Multivariate analysis of factors related to Delayed Graft Function
Linear regression analysis of clinical parameters related to delayed graft function (cold ischae-
mia time, donor age, type of organ donation) and CDKN2A/p16 expression revealed signifi-
cant associations with donor age and DCD status. Cold ischaemic time and CDKN2A/p16
expression were not significant in this model (Table 4 –model A).
Further multivariate analysis performed with the inclusion of microRNAs, revealed that
hsa-miR-217, hsa-miR-125b added additional power to the known clinical variables for
delayed graft function in a biologically plausible context (Table 4 –model B).
GRPSSmodel construction
Binary logistic regression was used with stepwise backwards conditional modelling to investi-
gate the importance of all factors in determining the presence/absence of DGF post-transplant.
This was applied to analyses for hsa-mir-217 and hsa-mir-125b expression levels relative to
clinical parameters, to determine their predictive ability for individual performance criteria in
the primary allograft cohort (n = 94). These included type of organ donation and previous
Table 3. Correlationmatrix of miRNA expression and renal allograft function at post-operative days 3 (POD3), 5 (POD5) and 7 (POD7).
Spearman's rho Post-operative day (POD) 3 Post-operative day (POD) 5 Post-operative day (POD) 5
Cr MDRD4 Cr MDRD4 Cr MDRD4
hsa-miR-125b cc -0.230* 0.221* -0.261* 0.238* -0.315** 0.298**
p 0.027 0.035 0.012 0.022 0.002 0.004
hsa-miR-217 cc -0.199 0.185 -0.186 0.208* -0.253* 0.256*
p 0.057 0.078 0.076 0.047 0.015 0.014
doi:10.1371/journal.pone.0146378.t003
Table 4. Regression analyses. A) Regression analysis of clinical parameters and CDKN2A only in the relation to Delayed Graft Function (DGF). B) Regres-
sion analysis of clinical and molecular parameters in multivariate model.
Variable (model A) Est Error T value P value
Donor Age 0.0095 0.0027 3.505 0.00083
CDKN2A 0.0075 0.0102 0.735 0.4650
DCD donor 0.3890 0.1110 3.573 0.0006
Cold Ischaemic Time 0.00016 0.0002 0.834 0.4073
Variable (model B) Est Error T value P value
Donor Age 0.00924 0.00238 3.874 0.0003
CDKN2A 0.00319 0.0090 0.354 0.7245
DCD donor 0.28216 0.1026 2.748 0.0078
Cold Ischaemic Time 0.0002 0.0002 0.855 0.3956
hsa-miR-125b -0.39993 0.1040 -3.843 0.0002
hsa-miR-217 -0.222 0.0637 -3.489 0.0009
doi:10.1371/journal.pone.0146378.t004
microRNA and DGF
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transplant. These were added to the model and subtracted based on significance of input to the
model. ECD criteria were not included as the specific formulation already includes donor age.
CIT was excluded from the analysis as its occurrence correlates with hsa-miR-125b (Table 5).
For these analyses DGF was defined as a need for dialysis within 7 days after transplanta-
tion, with the exception of post-operative hyperkalaemia.
Analysis of these microRNA expression levels, relative to the presence or absence of DGF
using such modelling, indicated a capacity to predict pre-transplant the occurrence of DGF in
83% of cases, with an overall sensitivity of 61% and a specificity of 91% as determined by the
prediction model. This model was tested in the context of type of organ donation, previous
transplantation, CIT and donor gender (Table 5). Comparison of the model accuracy for cor-
rect prediction of DGF in relation to confounding factors is summarized in Table 6.
A direct comparison of the microRNA model, which we have termed the Glasgow Renal
Performance Scoring System (GRPSS) with the most commonly used clinical method for deter-
mining allograft suitability in the UK, the UKKDRI [16] indicated that the GRPSS was better at
predicting DGF occurrence (Table 7, Fig 3).
It should be noted that UKKDRI is a general performance scoring system and is not
intended to solely detect the occurrence of DGF. The GRPSS is presented here as a method
which is accurate and specific for DGF issues post-transplant.
These findings were then validated in an independent cohort (n = 24) using the same com-
bination of microRNAs and donor age (S1 Data). This resulted in a model which successfully
classified 70% of cases as DGF or non-DGF, with a sensitivity of 60% and a specificity of 77%
however further analyses including type of organ donation and other confounding factors were
not performed due to the small sample size.
Discussion
We have clearly demonstrated that only miRNAs incorporated into a novel scoring system, the
GRPSS, employed pre-transplant to assess renal allograft biopsies, can with high sensitivity and
Table 5. Binary logistic regression analysis of correlatedmicroRNAs and clinical parameters with the respect to DGF—GRPSSmodel.
Variable B S.E. Sig. Odds ratio 95% C.I. for Odds ratio
Lower Upper
hsa-mir-217 -1.987 0.787 0.012 0.137 0.029 0.641
hsa-mir-125b -2.415 1.002 0.016 0.089 0.013 0.637
Donor age 0.069 0.021 0.001 1.072 1.028 1.118
Type of organ donation -1.865 0.721 0.010 0.155 0.038 0.636
doi:10.1371/journal.pone.0146378.t005
Table 6. Binary logistic regression analysis of correlatedmicroRNAs and clinical parameters with the respect to DGF. Classification table for
GRPSSmodel in relation to confounding factors.
Predicted DGF
Selected cases (S) All Previous transplantation Cold ischaemia time Gender
No Yes (S) Above 12h (S) Below 12h Male (S) Female
Observed DGF
No 91 83.3 90.7 92.6 75 85.3 87.5
Yes 61.5 80 71.4 73.7 57.1 83.3 62.5
Overall percentage 82.8 82.4 85.3 86.9 71 84.6 82.5
doi:10.1371/journal.pone.0146378.t006
microRNA and DGF
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specificity predict the occurrence of DGF post-transplant. Consequently, we believe that the
GRPSS has the potential to enhance current methodologies and advance the detection of poor
performing allografts before they are transplanted, resulting in improved personalised care for
transplant patients. In fact, this scoring system outperforms the UKKDRI scoring system for
the detection of DGF, although the UKKDRI system was designed to improve organ allocation
rather than detect specific post-transplant outcomes.
The molecular biology underpinning this modelling system is both consistent and biologi-
cally plausible. Both hsa-miR-217 and hsa-miR-125b, are associated with the regulation of the
expression of the CDKN2 locus which has a proven regulatory role in biological ageing and
renal function post-transplant [5,6,7]. Furthermore, these miRNAs have regulatory roles in
cell-cell adhesion and related signalling pathways. These include TGF-β signalling, MAPK,
PI3K-AKT, mTOR cascades, actin skeleton remodelling and endocytosis [17]. Notably, they
target pathways related to cell stress and survival in model organisms [18] and thus provide a
biological signature consistent with data derived from different taxa, including dipteran insects,
nematode worms, yeast as well as mammals. The TGF-β cascade has previously been linked to
renal function, both in a reno-protective capacity and in renal inflammation and fibrosis [19].
In particular, hsa-miR-125b and hsa-miR-217 are involved in the regulation of a broad
range of cellular/biological processes that intersect on the MAPK signalling and the PI3K-AKT
pathways. Critically, these link regulations of immune responses via modulation of T and B cell
receptor and chemokine signalling, as well as the remodelling of the extracellular matrix,
including regulation of actin cytoskeleton, adherence junction and focal adhesions [17], all of
which have proven roles in allograft performance. Notably, the MAPK signalling pathway has
Table 7. ROC analysis comparing GRPSSmodel for DGF with UKKDRI.
Test Result Variable(s) Area Std. Error Asymptotic Sig. Asymptotic 95% Conﬁdence Interval
Lower Bound Upper Bound
UKKDRI .636 .065 .041 .507 .764
GRPSS .865 .043 .000 .781 .948
doi:10.1371/journal.pone.0146378.t007
Fig 3. ROC analysis for GRPSS.
doi:10.1371/journal.pone.0146378.g003
microRNA and DGF
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been linked to both chronic and acute kidney disease, where it has a dual function, mediating
kidney injury responses as well as having a role in renal stress resistance [20].
Previous studies have also demonstrated that increased expression of hsa-miR-217 is associ-
ated with suppression of Ras/MAPK and PI3K-AKT [21,22], indicating that these pathways
may be up-regulated by the suppressed expression of this miRNA.
Interestingly, the MAPK and TGF-β cascades, play important roles in the regulation of
microRNA biogenesis and can induce specific phenotypes depending on cellular context [23].
It should also be noted that the TGF-β pathway is involved in the activation of a broad range of
MAPK pathway components including RAS/MEK/ERK1/2 or Rho/JNK, independently of
SMAD proteins, but still affecting their phosphorylation status and thus modulating their
activity as transcription factors.
hsa-miR-125b has been linked to the promotion of a pro-inflammatory state by the modula-
tion of numerous target genes including matrix metalloproteinase, growth factors and BCl2
family members. This miRNA is also critical for immunological host-defence responses and
autoimmunity, as well as immune cell differentiation and their responses to the external stimuli
i.e., IL-4 and INF-γ [24]. Our data indicate a role for such processes in determining the long-
term success of allograft transplantation. These data are also in keeping with previous reports
[25,26] and treatment regimes targeting leukocyte adhesion molecules, which have been shown
to be critical in a range of kidney disorders including allograft rejection [27,28].
Our data do not readily agree with recent studies which have focused solely on miRNA anal-
ysis in post-transplant renal allografts (12–26 months post-transplantation) [17]. These studies
describe miRNA profiles in kidneys that have already undergone acute rejection (AR) episodes,
which thus serve as a ‘finger print’ of extant rejection. Interestingly, some of these microRNAs
showed differential expression in pre-transplant biopsies, including hsa-miR-125b, indicating
a potentially ongoing role for these miRNAs in the development and progression of conditions
leading to AR.
One hypothesis in keeping with our observations, is that organs displaying more biological
age and consequently poorer post-transplant function [29] will have a higher risk of rejection,
due to ischemic, metabolic and physical trauma incurred during the transplant process, result-
ing in leakage of cellular chromatin and mitochondrial proteins from damaged cells in such
organs, which might trigger immune responses in the recipient. This hypothesis is in keeping
with the correlations we have observed between pre-transplant levels of miRNAs involved in
the regulation of cellular bio-ageing. The more senescent/damaged cells present within the
organ, the more intra-cellular material that might leak into the recipient circulation. Conse-
quently, the likelihood of poor post-transplant performance is dependent on the level of senes-
cence related pre-implantation damage in the organ; other factors may include tissue
remodelling, accumulation of ECM components and consequent promotion of a pro-inflam-
matory environment by senescent cells. Our data suggest a mechanism which involves organ
condition at point of acquisition combined with rapid response damage, via miRNA levels,
resulting in an acceleration of the senescence associated phenotype within the donor organ.
This accelerated bio-ageing which occurs between organ retrieval and transplantation ulti-
mately determines post-transplant outcomes. In this instance, we have demonstrated that the
levels of two such rapid response elements (hsa-miR-217 and hsa-miR-125b) are significantly
altered in organs which experience DGF post-transplantation
Our data provides clear evidence that pre-transplant analysis of miRNA related to cellular
bio-ageing, cell stress and damage responses is useful in determining post-transplant function
of renal allografts. We believe this work demonstrates the considerable potential of miRNAs
for assaying the status of donor organs, and to improve the assessment of marginal organs by
providing more accurate pre-transplant prediction of post-transplant function. Notably, the
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turnaround time for the assays involved in implementing this molecular analysis is only 4
hours, which is within the time window for organ cross matching, indicating the ease of clinical
translation of this approach. We therefore believe our findings merit larger scale studies to (a)
develop a robust predictive tool for donor organs, and (b) validate that tool in different
populations.
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